MedPath

The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin

Phase 3
Completed
Conditions
Epilepsy
Interventions
Registration Number
NCT00908453
Lead Sponsor
Nobelpharma
Brief Summary

The study is to evaluate safety, efficacy and pharmacokinetics of intravenously administered fosphenytoin in patients with neurosurgery, head trauma, epilepsy or status epilepticus who are requiring a loading dose of phenytoin.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • male or female, hospitalized patients 2 years of age or older
  • Adult patients or guardian for pediatric patients to provide written informed consent
Read More
Exclusion Criteria
  • patient with a history of hypersensitivity to hydantoins
  • patient with hypotension, sinus bradycardia, sino-atrial block, second or third degree A-V block, or Adams-Stokes syndrome
  • pregnant or nursing female patients
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
15mg/kg of loading dosefosphenytoin-
22.5mg/kg of loading dosefosphenytoin-
18mg/kg of loading dosefosphenytoin-
Primary Outcome Measures
NameTimeMethod
Incidence of adverse events8 to 12 days
Secondary Outcome Measures
NameTimeMethod
frequency and nature of seizures8 to 12 days

Trial Locations

Locations (1)

National Center of Neurology and Psychiatry

🇯🇵

Kodaira, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath